IL5 and Increased total eosinophil count: Phipps et al. and Flood-Page and colleagues found that patients with atopic asthma who received mepolizumab, an anti-IL5 antibody, exhibited a decrease in lung eosinophilia along with a reduction of markers of remodeling, suggesting a close association [13, 14].